Phase 1/2 Study of SEL24/MEN1703, a First-in-Class Dual PIM/FLT3 Kinase Inhibitor, in Patients With IDH1/2Mutated Acute Myeloid Leukemia: The DIAMOND-01 Trial

被引:0
作者
Martinelli, Giovanni [1 ]
Santoro, Armando [2 ]
Gambacorti-Passerini, Carlo [3 ]
Polo, Susana Vives [4 ,5 ]
Solomon, Scott R. [6 ]
Mukherjee, Sudipto [7 ]
Lech-Maranda, Ewa [8 ]
Levy, Moshe Yair [9 ]
Wierzbowska, Agnieszka [10 ]
Calbacho-Robles, Maria [11 ]
Marconi, Giovanni [1 ]
Giannini, Maria Benedetta [1 ]
Cano, Isabel [12 ]
Minana, Laura Torres [12 ]
Acuna-Cruz, Evelyn [12 ]
Angelosanto, Noemi [13 ]
Mughal, Tariq I. [14 ,15 ]
Galleu, Antonio [16 ]
Blotta, Simona [16 ]
Ravandi, Farhad [17 ]
Montesinos, Pau [12 ]
机构
[1] IRST Srl, IRCCS Ist Romagnolo Studio Tumori Dino Amadori, Meldola, Italy
[2] Humanitas Res Hosp, Dept Oncol, IRCCS, Milan, Italy
[3] Univ Milano Bicocca, Dept Med & Surg, Milan, Italy
[4] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Badalona, Spain
[5] Univ Autonoma Barcelona, Jose Carreras Leukemia Res Inst, Barcelona, Spain
[6] Northside Hosp Canc Inst, Atlanta, GA USA
[7] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland, OH 44106 USA
[8] Inst Hematol & Transfus Med, Dept Hematol, Warsaw, Poland
[9] Baylor Charles A Sammons Canc Ctr, Texas Oncol, Dallas, TX USA
[10] Med Univ Lodz, Dept Hematol, Lodz, Poland
[11] Ramon y Cajal Univ Hosp, Dept Hematol, Madrid, Spain
[12] La Fe Univ Hosp, Dept Hematol, Valencia, Spain
[13] Ryvu Therapeut, Clin Dev Hematol, Krakow, Poland
[14] Tufts Univ, Sch Med, Div Hematol Oncol, Boston, MA 02111 USA
[15] Stemline Therapeut Inc, New York, NY USA
[16] Menarini Grp, Global Oncol TA, Hematol Malignancies, Florence, Italy
[17] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
关键词
AML; acute myeloid; leukemia; FLT3-ITD; FLT3; inhibitor; IDH mutation; PIM kinase; Trial-in-Progress;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
AML-389
引用
收藏
页码:S243 / S244
页数:2
相关论文
empty
未找到相关数据